tbuckley/cabot-search huggingface dataset:
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
Authors: Hiromichi Shirasu, Takeshi Kawakami, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Tomoya Yokota, Kentaro Yamazaki, Akira Fukutomi, Yusuke Onozawa, Hirofumi Yasui
Journal: Journal of Clinical Oncology (2021)

407 Background: 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) is one of the preferred regimens for patients (pts) with advanced pancreatic cancer (APC) who received prior gemcitabine-based therapy in the National Comprehensive Cancer Network Guidelines. However, its survival benefit or safety in clinical practice is unclear. Methods: We retrospectively assessed the data of consecutive pts with APC who received FOLFIRI as a second or later-line treatment after gemcitabine-based therapy at Shizuoka Cancer Center between May 2014 and March 2020. Results: The characteristics of 102 pts included in this analysis were as follows: median age (range), 67 (39-78) y; male/female, 55/47; ECOG PS0/1/2, 21/72/9; the number of metastatic sites 0/1/2/3/4, 7/48/35/8/4; unresectable/recurrent, 84/18; UGT1A1 status wild/*6 or*28 heterozygous/homo or double-heterozygous/unknown, 40/40/5/17; treatment line of FOLFIRI 2nd/3rd/4th, 64/32/6. Previous treatment history according to the treatment line of FOLFIRI was as follows: 2nd-line, all patients received GEM-based regimen, GEM plus nanoparticle albumin bound paclitaxel in 63 pts (98.4%) and GEM in 1 (1.6%); 3rd, GEM-based and S1 in 20 (62.5%), GEM-based and 5-FU/levofolinate/oxaliplatin (FOLFOX) in 12 (37.5%); 4th, GEM-based, FOLFOX and S-1 or other agent in 5 (83.3%), 2 GEM-based regimens and S1 in 1 (16.7%). The median treatment cycle was 5 (range 1-55). The median treatment cycle according to the treatment line was as follows: 2nd-line, 7(1-55); 3rd, 4(1-14); 4th, 3.5(1-10). The initial dosage for each cytotoxic agent was as follows: bolus 5-FU injected/omited 72/30; continuous 5-FU 2400/2000/1200 mg/m 2 , 88/13/1; irinotecan 180/150/120/less than or equal to 100mg/m 2 , 27/59/13/3. The overall response rate (ORR) and disease control rate (DCR) were 5.9% and 52.9%, respectively. ORR and DCR according to the treatment line were as follows: 2nd-line, 9.3/64.1%; 3rd, 0/68.8%; 4th, 0/50.0%. At the median follow up 6.5 M, the median overall survival (OS) and progression free survival (PFS) were 6.6M and 3.1M, respectively. The median OS and PFS according to the treatment line were as follows: 2nd-line, 8.1/3.6M; 3rd, 5.1/2.1M; 4th, 6.6/2.0M. Adverse events (AEs) were observed in 70.8% pts. Grade 3 or higher AEs occurred in 27.2% pts [neutropenia in 26 (25.2%) pts, febrile neutropenia in 4 (3.9%) pts, nausea in 4 (3.9%) pts, decreased appetite in 3 (2.9%) pts]. No treatment related deaths were observed. Conclusions: FOLFIRI is well tolerated and effective especially in the second-line treatment for pts with gemcitabine-refractory APC.
The effects of armed conflict on the health of women and children
Authors: Eran Bendavid, Ties Boerma, Nadia Akseer, Ana Langer, Espoir Bwenge Malembaka, Emelda A Okiro, Paul H Wise, Sam Heft-Neal, Robert E Black, Zulfiqar A Bhutta, Zulfiqar Bhutta, Robert Black, Karl Blanchet, Ties Boerma, Michelle Gaffey, Ana Langer, Paul Spiegel, Ronald Waldman, Paul Wise
Journal: The Lancet (2021)
Infographic. COVID-19 RT-PCR testing for elite athletes
Authors: Alan Rankin, Andrew Massey, Éanna Cian Falvey, Todd Ellenbecker, Peter Harcourt, Andrew Murray, Denis Kinane, Bert Niesters, Nigel Jones, Rhodri Martin, Michael Roshon, Michael Edmund David McLarnon, James Calder, Dionisio Izquierdo, Babette M Pluim, Niall Elliott, Neil Heron
Journal: British Journal of Sports Medicine (2021)

This infographic outlines evidence-based recommendations on COVID-19 reverse transcriptase PCR (RT-PCR) testing in elite sport settings, aiming to protect personal and population health, and acknowledging resources and expertise that are often available in elite sport. Public health recommendations vary by country and region, and protocol decisions should be made in consultation with relevant public health authorities.



An expert, multidisciplinary group with input from clinical virology, microbiology, public health, infectious diseases and sports medicine provides optimal implementation and interpretation of testing.

Interventions to prevent COVID-19 transmission should be implemented consistently1 2 and should include

The current gold standard of testing is RT-PCR testing.4–6 The test is highly sensitive and specific to SARS-CoV-2 viral RNA in laboratory conditions.2 Test results should be interpreted on the basis of the pretest probability, previous test …
Abstract 15935: De Novo Subcutaneous Implantable Cardioverter-Defibrillator Placed in Patient With Left Ventricular Assist Device
Authors: Emrie Tomaiko, Aneesh Kalya, Marie Olsen, Heather Bahm, Sharon Kusne, Carla Lockhart, Wilber Su
Journal: Circulation (2019)

Introduction: Methods: A 77-year-old male with history of ischemic systolic heart failure, New York Heart Association (NYHA) Class IV, and HeartMate II LVAD implantation presented to the hospital f...
AB0094 Prevalence of twin births in behÇet’s disease (bd)
Authors: S Masatlýoðlu, F Göðüþ, B Yýldýrým, R Tunç, I Fresko, H Yazýcý
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> Studies of twins in BD have been few.<sup>1,2</sup> Our clinical impression has been that patients with BD had a paucity of twin siblings. We studied the frequency of twin siblings among the BD patients in a controlled protocol. <h3>Methods</h3> 1277 patients (773 males and 504 females with a mean age of 34.20 ± 9.59 years) attending a dedicated BD outpatient clinic were asked whether they had a twin sibling, living or dead. Inquiry into monozigosity was made by asking whether this twin (s) looked exactly like the proband as 'two peas in a pod'.<sup>3</sup> As controls the same information was sought among i. a group of patients with either rheumatoid arthritis (RA) or systemic lupus (SLE), composed of 180 patients with RA -150 males and 30 females with a mean age of 49.08 ± 14.05 years- and 79 patients with SLE -64 females and 15 males with a mean age of 34.80 ± 12.33 years- all attending a rheumatology outpatient clinic; and ii. among 7761 first year university students -3848 males and 3913 females with a mean age of 18.55 ± 1.38 years- during their university registration. Chi-square test (2<sub>df</sub>) was used to compare the findings between the three groups. <h3>Results</h3> Among the 7761 university students, 120 twins (1.5%) were identified. 92 were dizygotic (1.2%) and 28 (0.38%) monozygotic. Among the 259 patients with connective tissue disease there were 7 (2.7%), all dizygotic twins. Two twins belonged to the SLE and 5 to the RA patients. Among the 1277 patients with BD there were 10 twins (0.08%; x<sup>2</sup><sub>2df</sub> = 7.17, p = 0.03). Eight were dizygotic and 2 (0.15%; p &gt; 0.12) were monozygotic. The monozygotic twins were discordant for BD in either case. <h3>Conclusion</h3> The frequency of twin births among our controls was similar to that reported in general for twin-births.<sup>4</sup> The rather marked decrease, 19 fold when compared to the group of university students and 34 fold when compared to the group of patients with RA or SLE, in the twin frequency among the BD patients could be due to the presence of in utero factors operative in the mothers of patients with BD, unfavourably affecting the successful initiation and/or completion of a twin pregnancy. <h3>References</h3> Hamuryudan V, <i>et al</i>. Arhtritis Rheum. 1991;34(8):1071-2 Gül A, <i>et al</i>. Br J Rheumatol. 1997;36(8):922–7 Cederlöf R, <i>et al</i>. Arch Environ Health 1967;14:401 Mac Gillivray I. Semin Perinatal. 1986;10(1):4–8
Physician Performance in the Medicare Merit-based Incentive Payment System
Authors: Vinay K. Rathi
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
Authors: Feng Wang, Yu Qi, Xiangrui Meng, Qingxia Fan
Journal: Journal of Clinical Oncology (2021)

222 Background:At present, esophageal cell carcinoma (ESCC) has a dismal prognosis with huge unmet clinical needs. With the potential benefit of combining PD-1 inhibitor with neoadjuvant chemotherapy (nCT), we conducted a phase II trial to assess the efficacy and safety of Camrelizumab (anti-PD-1 antibody) plus nCT for locally advanced ESCC. Methods:26 patients (pts) with histologically confirmed stage Ⅱ/Ⅲ/Ⅳa (cT2-4aN0-3M0) ESCC were enrolled from February 2020 to September 2020.The study was divided into two stages, stage1: we administered 1 cycle of Camrelizumab for induction therapy (200 mg q2 weeks); stage2: pts received 2 cycles of Camrelizumab (200 mg every 3 weeks) plus docetaxel and nedaplatin, followed by surgery within 4~6 weeks after neoadjuvant therapy completion. Primary endpoint was major pathologic response (MPR). Secondary endpoints included pathologic complete response (pCR), R0 resection rate, disease-free survival (DFS) and overall survival (OS). In total 40 pts will be enrolled. Results:At the cutoff date of Sep 22, 2020, 26 eligible pts were enrolled (65% males, median age 63), neoadjuvant treatment was completed in 17 pts and is ongoing in 7 pts. Thus far 12 out of 17 pts were resected, 5 pts are planned to undergo surgery, 1 pt had interval metastases preoperatively, 1 pt declined surgery. All patients underwent an R0 resection. Postoperative pathology showed that T stage decreased in 10 pts with 83% reduction rate. 5 pts (42%) reached major pathologic response, 3 pts (25%) reached pathologic complete response, the others maintained stable disease (33%). No grade 3 immunotherapy related AEs were observed, no surgery related mortality. The most common AEs (all grade, grade≥3) were anemia (31%, 3%), leukopenia (7%, 0%), neutrophil (3%,0%), hypoalbuminemia (21%, 0%), hematochezia (14%, 0%), fatigue (10%, 0%) and thyroid dysfunction (24%, 0% ). Date for median PFS and OS were not matured. Conclusions:Camrelizumab in combination with preoperative chemotherapy followed by surgery for locally advanced ESCC showed promising downstaging effect and MPR with good tolerance, and its efficacy and safety could be further studied in later trials. Clinical trial information: NCT03917966.
THU0013 Biological and immunological profiles of the delta-selective opioid receptor antagonist hs 378
Authors: M Spetea, H Erlandsson-Harris, I Berzetei-Gurske, L Klareskog, H Schmidhammer
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Immuno-hyperreactivity is a fundamental process in inflammatory conditions such as rheumatoid arthritis. Delta-selective opioid receptor antagonists have been shown to exhibit inhibitory effects on inflammation. Therefore, the development of such compounds is highly promising with regard to selective action and is also of potential clinical relevance for human inflammatory diseases. HS 378 is a recently developed indolomorphinan with high selectivity and antagonist potency at the delta-opioid receptor. <h3>Objectives</h3> The present study was performed to characterise the opioid binding properties and pharmacological and immunological activity of HS 378 and to compare them with those of two well-known delta-opioid receptor antagonists, naltrindole and naltriben. <h3>Methods</h3> In vitro opioid receptor binding profiles were determined in rat brain homogenates. Agonist/antagonist potency of HS 378 was determined in the [<sup>35</sup>S]GTPγS functional assay using membranes from CHO cells transfected with cloned human opioid receptors. In order to assess immunological activity, HS 378 was tested on concanavaline a stimulated rat T-lymphocytes. <h3>Results</h3> HS 378 showed 4.7- and 2.4-fold higher mu/delta selectivity compared to naltrindole and naltriben, respectively. In the [<sup>35</sup>S]GTPγS functional assay, HS 378 resulted in an apparent dose-related suppression of concanavaline A induced rat T-lymphocyte proliferation with an IC<sub>50</sub> value of 0.54 μM. The IC<sub>50</sub> of HS 378 was 13 times lower than that of naltrindole and 8 times higher than that of cyclosporine A. <h3>Conclusion</h3> Taken together, our findings indicate that the small molecule HS 378 has properties that may be of therapeutic value in the setting of human inflammatory diseases.
SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study
Authors: Sanjay Pandanaboyana, John Moir, John S Leeds, Kofi Oppong, Aditya Kanwar, Ahmed Marzouk, Ajay Belgaumkar, Ajay Gupta, Ajith K Siriwardena, Ali Raza Haque, Altaf Awan, Anita Balakrishnan, Arab Rawashdeh, Bogdan Ivanov, Chetan Parmar, Christopher M Halloran, Clifford Caruana, Cynthia-Michelle Borg, Dhanny Gomez, Dimitrios Damaskos, Dimitrios Karavias, Guy Finch, Husam Ebied, James K Pine, James R A Skipworth, James Milburn, Javed Latif, Jeyakumar Ratnam Apollos, Jihène El Kafsi, John A Windsor, Keith Roberts, Kelvin Wang, Krish Ravi, Maria V Coats, Marianne Hollyman, Mary Phillips, Michael Okocha, Michael SJ Wilson, Nadeem A Ameer, Nagappan Kumar, Nehal Shah, Pierfrancesco Lapolla, Connor Magee, Bilal Al-Sarireh, Raimundas Lunevicius, Rami Benhmida, Rishi Singhal, Srinivasan Balachandra, Semra Demirli Atıcı, Shameen Jaunoo, Simon Dwerryhouse, Tamsin Boyce, Vasileios Charalampakis, Venkat Kanakala, Zaigham Abbas, Manu Nayar
Journal: Gut (2021)

There is emerging evidence that the pancreas may be a target organ of SARS-CoV-2 infection. This aim of this study was to investigate the outcome of patients with acute pancreatitis (AP) and coexistent SARS-CoV-2 infection.
Preservatives in Food and Food Examination.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Circadian Syndrome Predicts Cardiovascular Disease Better than Metabolic Syndrome in Chinese Adults
Authors: Zumin Shi, Jaakko Tuomilehto, Noga Kronfeld-Schor, George Alberti, Naftali Stern, Assam El-Osta, Carmel Bilu, Haim Einat, Paul Zimmet
Journal: Metabolism (2021)
HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses
Authors: Kiera L. Clayton, Geetha Mylvaganam, Alonso Villasmil-Ocando, Heather Stuart, Marcela V. Maus, Mohammad Rashidian, Hidde L. Ploegh, Bruce D. Walker
Journal: Cell Host & Microbe (2021)
Immune Predictors of Death versus Survival in COVID-19 ICU Pneumonia Patients on Mechanical Ventilators
Authors: Natalia Antonevich, Andrei Hancharou, Alena Rynda, Marina Dotsenko, Eduard Dotsenko, Alena Halavach, Oxana Timohina, Yana Minich, Darya Babrukevich, Lawrence Dubuske
Journal: Journal of Allergy and Clinical Immunology (2021)

The outcome of COVID-19 associated pneumonia is strongly related to the host immune response. This investigation seeks to identify immune markers of the clinical outcome COVID 19 pneumonia in an ICU. 18 patients with PCR and chest CT confirmed diagnosis of severe/critical COVID-19 pneumonia were included in the study. Patients were treated in an ICU and required ventilation (IMV). 10 patients died (D) and 8 survived (S). Blood samples from 19 healthy donors (HD) controls were also assessed. Blood myeloid (myeloid suppressor cells, monocytes, dendritic cells (DC)) and lymphoid cells (T, B, ILC, NK, NKT cells and subsets) subsets as well as neutrophil and monocyte activation markers (CD35, CD32, CD88, CD282) were assayed. Nonparametric statistics, cluster and ROC analysis were applied. More than 100 parameters analyzed in COVID-19 patients allowed definition of considerable alteration of both lymphoid and myeloid immune compartments. 3 parameters were associated with unfavorable outcomes: decreased frequencies of myeloid DC (mDC) and increased numbers of M-MDSC and B-cells. Cluster analysis using these selected parameters precisely divided patients in the ICU into 2 groups: D and S. ROC analysis allowed calculation of the sensitivity and specificity of each parameter and cut-points (mDC – 95.9%/100%/<0.02%; M-MDSC – 85.7%/86.2%/>12.6%; B-cells – 91.8%/86.2%/>19.1%). Extremely low frequencies of mDC in peripheral blood, 4-5 fold increased content of M-MDSC, and an increased relative content of B cells in COVID 19 patients versus HD were identified as predictors of death in COVID-19 associated pneumonia patients ventilated in an ICU.
NHS reorganisation must not be rushed through during pandemic, leaders warn
Authors: Elisabeth Mahase
Journal: BMJ (2021)

The government’s proposed reorganisation of the NHS in England must not be rushed through at a time when “physically and emotionally exhausted” staff are still dealing with the covid-19 pandemic, the BMA has warned.

BMA council chair Chaand Nagpaul said the NHS was facing the greatest backlog of care ever on top of the continuing pressure of covid-19. Dealing with this would require “significant new resources and an immediate action plan,” and investment must not be diverted to the reorganisation, he said.

“Proposals for sweeping reorganisation on such a scale will need greater time for consideration and must not be rushed through while doctors are still tackling the winter surge in …
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
Authors: Fabrice Barlesi, Judith Raimbourg, Pascal Do, Patrick Dumont, Jacques Cadranel, Didier Debieuvre, Werner Hilgers, Pierre Jean Souquet, Olivier Molinier, Elisabeth A. Quoix, Alexandra Langlais, Marie Paule Lebitasy, Franck Morin, Gerard Zalcman, Jaafar Bennouna
Journal: Journal of Clinical Oncology (2016)

9077 Background: Pemetrexed (Pem) + Cisplatine (Cis) + Bevacizumab (Bev) followed with maintenance therapy (Bev and/or Pem) is a therapeutic standard in advanced non-squamous NSCLC. Methods: A single arm phase II trial aimed to evaluate a stop and go strategy: Sequence 1: 3 cycles Pem 500 mg/m² + Cis 75 mg/m² + Bev 7.5 mg/kg q3 weeks, followed by maintenance Bev 7.5 mg/kg/3 week until progression ; sequence 2: reintroduction Pem + Cis + Bev, 3 cycles, Pem + Bev maintenance until progression. Primary endpoint: at least 75% of patients in the sequence 2 received the 3 cycles without cisplatin/carboplatin dose modification. Results: from Dec. 2012 to Aug. 2014, 120 patients (77 males) were included in 14 French hospitals: PS 0 (50%); median age 60.6 y (36.0 – 77.3). Of 113 eligible patients, 65 (57.5 %) were treated in sequence 2. 37 patients (56.9%, IC95% [45.1%-73.6%]) received the 3 cycles (sequence 2) at full dose; 86 % (n = 56) with or without dose reduction. At sequence 2, specific bev-induced grade 3 – 4 toxicity was reported in 7 (10.3%) patients (1 grade 5 haemoptysis). Median follow-up was 27.1m [24.7-29.6]. Secondary objectives showed a median Progression-Free Survival 1 (PFS1) (inclusion – progression 1) 5.8 m (IC95%:5.0 – 6.3); median PFS2 (progression 1 – progression 2) 6.6 m (IC95%:5.7 – 8.4); median duration of disease control (PFS1 + PFS 2) (n = 65) 11.4 m (IC95:10.1 – 13.4). Objective response rate after sequence 2 was 15.4% (IC95%: 6.6-24.2) with 60% of stable disease. The median overall survival for eligible population was 17.7 m (IC95% 13.1 – 21.6) and 20.5 m (16.9 – NR) for patients who reached the sequence 2 (n = 65). Conclusions: Although the stringent primary endpoint was not met, this study highlighted that a ‘stop and go’ strategy using a platinum-based chemotherapy with bevacizumab continuation beyond progression, compares favourably with standard schedule, deserving to be further studied in non-squamous advanced NSCLC. Clinical trial information: NCT01705184.
A positive perception of treatment and continued adherence to dosing in a long-term follow-up study in food allergic participants undergoing multi-food oral immunotherapy
Authors: Sayantani Sindher, Divya Kumar, Jessica Fitzpatrick, Shu Cao, Andrew Long, Margaret Woch, Tiffany Conn, Kari Nadeau, Sharon Chinthrajah
Journal: Journal of Allergy and Clinical Immunology (2021)
Abstract 10874: Coronary Revascularization Trends in the United States, 2000-2014
Authors: Hua Hao, Varun Pattisapu, Yong Cen, David Shavelle
Journal: Circulation (2019)

Introduction: Coronary revascularization is among the most common hospital-based procedures/surgeries performed in the United States (US). Prior studies have shown decreasing rates of revasculariza...